BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35618235)

  • 1. Impact of Grade on Survival in Pleomorphic Xanthoastrocytoma and Low Prevalence of BRAF V600E Mutation.
    Gandham EJ; Goyal-Honavar A; Beno D; Pai R; Balakrishan R; Jasper A; Gowri M; Moorthy RK; Chacko AG; Chacko G
    World Neurosurg; 2022 Aug; 164():e922-e928. PubMed ID: 35618235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, Morphological, and Molecular Study on Grade 2 and 3 Pleomorphic Xanthoastrocytoma.
    Zhang H; Ma XJ; Xiang XP; Wang QY; Tang JL; Yu XY; Xu JH
    Curr Oncol; 2023 Feb; 30(2):2405-2416. PubMed ID: 36826144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
    Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
    World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.
    Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D
    Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.
    Dias-Santagata D; Lam Q; Vernovsky K; Vena N; Lennerz JK; Borger DR; Batchelor TT; Ligon KL; Iafrate AJ; Ligon AH; Louis DN; Santagata S
    PLoS One; 2011 Mar; 6(3):e17948. PubMed ID: 21479234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebellar pleomorphic xanthoastrocytoma in the setting of neurofibromatosis type-I: Does it portend a different prognosis? A case report and systematic review.
    Mathkour M; Banerjee S; Werner C; Hanna J; Abou-Al-Shaar H; Dindial R; Scullen T; Boehm L; Tubbs RS; Ware ML
    Clin Neurol Neurosurg; 2021 Jan; 200():106346. PubMed ID: 33160715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
    Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
    Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI characteristics predict BRAF V600E status in gangliogliomas and pleomorphic xanthoastrocytomas and provide survival prognostication.
    Jiang B; Zheng Y; She D; Xing Z; Cao D
    Acta Radiol; 2024 Jan; 65(1):33-40. PubMed ID: 37401109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
    Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
    J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF-Mutated Pleomorphic Xanthoastrocytoma of the Spinal Cord with Eventual Anaplastic Transformation.
    Hong CS; Wang JL; Dornbos D; Joehlin-Price A; Elder JB
    World Neurosurg; 2017 Feb; 98():871.e9-871.e15. PubMed ID: 27956254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
    Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
    Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
    Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
    Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
    Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
    J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group.
    Ono T; Sasajima T; Shimizu H; Natsumeda M; Kanamori M; Asano K; Beppu T; Matsuda K; Ichikawa M; Fujii Y; Ohkuma H; Ogasawara K; Sonoda Y; Saito K; Nobusawa S; Nakazato Y; Kitanaka C; Kayama T; Tominaga T;
    Neurol Med Chir (Tokyo); 2020 Nov; 60(11):543-552. PubMed ID: 33071274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells.
    Barresi V; Simbolo M; Ciaparrone C; Pedron S; Mafficini A; Scarpa A
    Histopathology; 2022 Nov; 81(5):661-669. PubMed ID: 35945679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring prognostic factors and treatment strategies for long-term survival in pleomorphic xanthoastrocytoma patients.
    Lee C; Byeon Y; Kim GJ; Jeon J; Hong CK; Kim JH; Kim YH; Cho YH; Hong SH; Chong SJ; Song SW
    Sci Rep; 2024 Feb; 14(1):4615. PubMed ID: 38409363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.
    Tonse R; Gupta T; Epari S; Shastri JG; Gurav M; Bano N; Jalali R
    J Neurooncol; 2018 Jan; 136(2):343-350. PubMed ID: 29147864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.